article = {SCR-2020-7-116}
title = {Hyperthermic Intra-Abdominal Chemotherapy with Gemcitabine as an Adjuvant Locoregional Treatment After Radical Surgery in Pancreatic Cancer}
journal = {Surgical Case Reports}
year = {2020}
issn = {2613-5965}
doi = {http://dx.doi.org/10.31487/j.SCR.2020.07.16}
url = {https://www.sciencerepository.org/hyperthermic-intra-abdominal-chemotherapy-with-gemcitabine-as-an-adjuvant_SCR-2020-7-116 
author = {Esther Pilar García Santos,David  Padilla-Valverde,Susana  Sánchez-García,M. Carmen  Manzanares-Campillo,Alejandro  Puerto-Puerto,Marta  Rodríguez-Martínez,Lucía  González-López,Jesús  Martín-Fernández,}
keywords = {HIPEC, pancreatic cancer, tumor stem cells}
abstract ={Purpose: The aim of our study is to present a series of patients in whom we have administered HIPEC
therapy.
Material and Methods: The treatment consists in performing cytoreductive surgery in patients diagnosed
with potentially resectable pancreatic adenocarcinoma, together with the administration of HIPEC therapy
with Gemcitabine. The dose of the drug is 120 mg/m2
for 30 minutes, followed by a conventional adjuvant
treatment.
Results: Five patients diagnosed with pancreatic adenocarcinoma have undergone surgery with a curative
nature. There were no technical or hemodynamic complications during the procedure.
Discussion: The use of HIPEC could achieve a decrease in the tumor progression of pancreatic cancer,
improving the survival of the patient, and decreasing the recurrence of the disease. A larger number of
patients will be necessary, as well as a long-term evaluation to assess the possible increase in survival in
this group of patients.}